Jasper Other Current Liab from 2010 to 2025

JSPRW Stock  USD 0.15  0.05  25.00%   
Jasper Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2025. During the period from 2010 to 2025, Jasper Therapeutics Other Current Liabilities regression line of quarterly data had mean square error of 2.8 T and geometric mean of  2,221,749. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
8.3 M
Current Value
8.8 M
Quarterly Volatility
2.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 11.2 M or Other Operating Expenses of 40 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.99. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Jasper Therapeutics Correlation against competitors.
For more information on how to buy Jasper Stock please use our How to Invest in Jasper Therapeutics guide.

Latest Jasper Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Jasper Therapeutics over the last few years. It is Jasper Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jasper Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Jasper Other Current Liab Regression Statistics

Arithmetic Mean2,956,275
Geometric Mean2,221,749
Coefficient Of Variation90.26
Mean Deviation2,028,572
Median1,370,000
Standard Deviation2,668,385
Sample Variance7.1T
Range7.4M
R-Value0.80
Mean Square Error2.8T
R-Squared0.64
Significance0.0002
Slope447,173
Total Sum of Squares106.8T

Jasper Other Current Liab History

20258.8 M
20248.3 M
20237.3 M
20223.6 M
20213.1 M
20202.6 M

About Jasper Therapeutics Financial Statements

Jasper Therapeutics investors use historical fundamental indicators, such as Jasper Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jasper Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities8.3 M8.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.